Liver Transplant CGM
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorIcahn School of Medicine at Mount Sinai
About this trial
This investigator initiated study aims to describe continuous glucose monitoring (CGM) based glycemic metrics after discharge from liver transplant and assess relationship with glycemic metrics and liver transplant outcomes.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
None
Disqualifiers
having a planned discharge to a rehabilitation or nursing facility,
a contraindication to sensor placement,
if discharge is anticipated to be >30 days post-transplant, or
if recent transplant also included a kidney or pancreas transplant
Trial population
inpatient liver transplant participants who have had an inpatient glucose greater than 180mg/dL
Trial design
Design model
Case-only
Time perspective
Prospective
Treatments tested in this trial
Libre 3+
DeviceBlinded CGM will be worn by all participants
Treatment groups
40 Participants
are divided into 1 treatment groupGroup A: Participants post liver transplant1 intervention
Trial outcomes
Primary outcomes
1
Time in range
Time in range 70-180mg/dL
Time frame
28 daysSecondary outcomes
1
Percent time >180mg/dL
Percent time \>180mg/dL
Time frame
28 days2
Percent time >250mg/dL
Percent time \>250mg/dL
Time frame
28 days3
Percent time <70mg/dL
Percent time \<70mg/dL
Time frame
28 days4
Percent time <54mg/dL
Percent time \<54mg/dL
Time frame
28 daysSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov